High prevalence of modifiable stroke risk factors identified in a pharmacy-based screening programme

Open Heart

Volumn 3, Issue 2, 2016, Pages

  Sandhu, Roopinder K ^a   Dolovich, Lisa ^b   Deif, Bishoy ^c   Barake, Walid ^a   Agarwal, Gina ^b   Grinvalds, Alex ^c   Lim, Ting ^c   Quinn, F Russell ^d   Gladstone, David ^e   Conen, David ^f   Connolly, Stuart J ^c   Healey, Jeff S ^c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLOOD PRESSURE MEASUREMENT; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HUMAN; HYPERTENSION; MALE; PHARMACY; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCREENING;

EID: 85007597294     PISSN: None     EISSN: 20533624     Source Type: Journal    
DOI: 10.1136/openhrt-2016-000515     Document Type: Article

References (31)

1. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-25.
2. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 2005;36:1115-19.
3. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019-26.
4. Wolf PA, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998;158:229-34.
5. Mittmann N, Seung SJ, Hill MD, et al. Impact of disability status on ischemic stroke costs in Canada in the first year. Can J Neurol Sci 2012;39:793-800.
6. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67.
7. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-62.
8. Lowres N, Neubeck L, Redfern J, et al. Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost 2013;110:213-22.
9. Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012;28:125-36.
10. Furberg CD, Psaty BM, Manolio TA, et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994;74:236-41.
11. Engdahl J, Andersson L, Mirskaya M, et al. Stepwise screening of atrial fibrillation in a 75-year-old population: implications for stroke prevention. Circulation 2013;127:930-7.
12. Svennberg E, Engdahl J, Al-Khalili F, et al. Mass screening for untreated atrial fibrillation: the STROKESTOP study. Circulation 2015;131:2176-84.
13. Lowres N, Neubeck L, Salkeld G, et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost 2014;111:1167-76.
14. Benrimoj SI, Frommer MS. Community pharmacy in Australia. Aust Health Rev 2004;28:238-46.
15. Shiu JR, Simpson SH, Johnson JA, et al. Quantifying opportunities to affect diabetes management in the community. Can Pharm J 2006;139:37-8.
16. Tsuyuki RT, Johnson JA, Teo KK, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med 2002;162:1149-55.
17. Kaczorowski J, Chambers LW, Dolovich L, et al. Improving cardiovascular health at population level: 39 community cluster randomised trial of Cardiovascular Health Awareness Program (CHAP). BMJ 2011;342:d442.
18. Peterson GM, Fitzmaurice KD, Kruup H, et al. Cardiovascular risk screening program in Australian community pharmacies. Pharm World Sci 2010;32:373-80.
19. Tsuyuki RT, Houle SK, Charrois TL, et al. Randomized Trial of the Effect of Pharmacist Prescribing on Improving Blood Pressure in the Community: the Alberta Clinical Trial in Optimizing Hypertension (RxACTION). Circulation 2015;132:93-100.
20. Santschi V, Chiolero A, Burnand B, et al. Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. Arch Intern Med 2011;171:1441-53.
21. Lowres N, Krass I, Neubeck L, et al. Atrial fibrillation screening in pharmacies using an iPhone ECG: a qualitative review of implementation. Intern J Clin Pharm 2015;37:1111-20.
22. Canadian Task Force on Preventive HealthPottie K, Jaramillo A, Lewin G, et al. Recommendations on screening for type 2 diabetes in adults. CMAJ 2012;184:1687-96.
23. Proietti M, Mairesse GH, Goethals P, et al. A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme. Europace 2016. [Epub ahead of print]. doi:10. 1093/europace/euw069
24. Tarn DM, Paterniti DA, Wenger NS, et al. Older patient, physician and pharmacist perspectives about community pharmacists' roles. Int J Clin Pharm 2012;20:285-93.
25. Terner M, Reason B, McKeag AM, et al. Chronic conditions more than age drive health system use in Canadian seniors. Healthc Q 2011;14:19-22.
26. Pharmacists regarded as the most trusted profession for a second year running! CNW A PR Newswire Company 2012. http://www. newswire. ca
27. Kaasenbrood F, Hollander M, Rutten FH, et al. Yield of screening for atrial fibrillation in primary care with a hand-held, single-lead electrocardiogram device during influenza vaccination. Europace 2016;18:1514-20.
28. Healey JS, Sandhu RK. Are we ready for mass screening to detect atrial fibrillation Circulation 2015;131:2167-8.
29. Fitzmaurice DA, Hobbs FD, Jowett S, et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ 2007;335:383.
30. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016;18:1609-78.
31. Taggar JS, Coleman T, Lewis S, et al. Accuracy of methods for diagnosing atrial fibrillation using 12-lead ECG: a systematic review and meta-analysis. Int J Cardiol 2015;184:175-83.